Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Gun Violence Trauma
  • Maternal Mortality
  • Hospital Food
  • Medicaid Work Requirements
  • Visa Program Delays

TRENDING TOPICS:

  • Gun Violence Trauma
  • Maternal Mortality
  • Hospital Food
  • Medicaid Work Requirements
  • Visa Program Delays

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Aug 2 2019

Full Issue

Trendy CBD With Its Myriad Of Promises Attracts Attention From Major Consumer Health Companies

While the benefits of most CBD-based products remain to be proven in tests, research estimates the U.S. market will reach almost $24 billion by 2023. News on medical marijuana comes out of Oregon, Louisiana, Missouri and Colorado.

Bloomberg: CBD Piques Consumer Health Giants’ Interest As Market Takes Off 

CBD, the trendy cannabis extract increasingly used to relieve pain, anxiety and insomnia, is attracting the interest of the biggest consumer-health companies. The venture formed by pharma giants GlaxoSmithKline Plc and Pfizer Inc. is studying CBD as part of an effort to ensure it’s the No. 1 consumer pain relief company in the world, Chief Executive Officer Brian McNamara said in an interview Thursday after the companies announced the transaction was complete. The new entity hasn’t made any decisions, he said. (Paton and Milligan, 8/1)

The Oregonian: Wilsonville Mom Loses Bid To Treat 13-Year-Old’s Cancer With CBD, Not Surgery

After months of argument about whether Oregon should strengthen its requirement that all children be vaccinated, the debate about how far an Oregon parent’s right to refuse established medical advice is back on the national radar. This time it involves CBD, a flashpoint in medical research as cannabis is slowly legalized. Kylee Dixon, 13, became an emblem of the debate when her mother, Christine, was accused of defying a court order to deliver Kylee to state care in order to prevent her from getting a surgery to remove a cancerous tumor from her liver. (Harbarger, 8/1)

The Associated Press: Medical Marijuana Cleared For Release To Louisiana Patients 

Medical marijuana is expected to start reaching select dispensaries in Louisiana on Tuesday, after the state agriculture department completed final testing and cleared therapeutic cannabis for release to patients. Agriculture Commissioner Mike Strain announced Thursday evening that GB Sciences, one of two state-sanctioned growers, can begin shipping out the product to Louisiana’s registered dispensaries. Strain thanked “everyone who has worked tirelessly from inception through production and testing to make this a reality.” (Deslatte, 8/1)

KCUR: Why Black Entrepreneurs In Kansas City Might Be Left Out Of The Medical Marijuana Boom 

Missouri starts officially accepting applications for medical marijuana businesses Saturday, and it’s a potentially lucrative business: A cannabis data research company estimates that by 2025, Missouri could see $111 million in medical marijuana sales yearly. But [Angela] Boykin and other applicants are black, and even though Missouri by law can’t factor in race or gender when awarding licenses, the national trend is that pot business owners and founders are overwhelmingly white. (Okeson-Haberman, 8/1)

Kaiser Health News: Colorado Doctors Note The Challenges In Treating Marijuana Users Who Undergo Surgery

When Colorado legalized marijuana, it became a pioneer in creating new policies to deal with the drug. Now the state’s surgeons, nurses and anesthesiologists are becoming pioneers of a different sort in understanding what weed may do to patients who go under the knife. Their observations and initial research show that marijuana use may affect patients’ responses to anesthesia on the operating table — and, depending on the patient’s history of using the drug, either help or hinder their symptoms afterward in the recovery room. (Ruder, 8/2)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF